Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MnB vaccine rLP8026 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Experimental (20ug); Active Comparator/Placebo |
| Cohort 2 | EXPERIMENTAL | Experimental (60ug); Active Comparator/Placebo |
| Cohort 3 | EXPERIMENTAL | Experimental (200ug); Active Comparator/Placebo |
| Name | Type | Description |
|---|---|---|
| MnB vaccine rLP8026 | BIOLOGICAL | MnB vaccine at 20ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively) |
Inclusion Criteria * Aged 18- to 36-months * Healthy male or female subjects Exclusion Criteria * Prior vaccination with a serogroup B meningococcal vaccine * Prior history of any invasive meningococcal disease
MnB vaccine rLP8026 is an investigational vaccine being studied for use in healthy individuals. It is being evaluated for safety and immunogenicity in healthy toddlers aged 18 months and older. The vaccine is currently in Phase 1 clinical development and has not been approved for any indication.
MnB vaccine rLP8026 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. Pfizer is conducting clinical trials to evaluate the safety and immunogenicity of this investigational vaccine in healthy toddlers.
MnB vaccine rLP8026 is in Phase 1 clinical development. It is an investigational vaccine that has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the vaccine remains under investigation for use in healthy individuals.
MnB vaccine rLP8026 has been studied in one completed Phase 1 clinical trial with the identifier NCT00387569. This trial, titled 'Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Healthy Toddlers,' enrolled 99 healthy participants aged 18 months and older in Australia. The trial was randomized, double-blind, and controlled.
Yes, MnB vaccine rLP8026 is also known as rLP2086. The completed Phase 1 clinical trial NCT00387569 evaluated the safety and immunogenicity of the rLP2086 vaccine in healthy toddlers. This alternative name is used in the clinical trial record for the same investigational vaccine.